Vicore Pharma Holding AB (publ) (VCRE)
NASDAQ: VCRE · Real-Time Price · USD
10.40
+0.39 (3.90%)
Nov 6, 2026, 4:00 PM EST - Market closed
Vicore Pharma Holding AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3.83 | 3.82 | 109.35 | - | - | - | |
Revenue Growth | -54.97% | -96.51% | - | - | - | - |
Gross Profit | 3.83 | 3.82 | 109.35 | - | - | - |
Selling, General & Admin | 107.05 | 67.91 | 50.44 | 44.6 | 37.53 | 21.61 |
Research & Development | 449.65 | 390.35 | 249.26 | 276.29 | 249.97 | 271.81 |
Other Operating Expenses | 1.61 | - | - | - | - | - |
Operating Expenses | 558.31 | 458.26 | 299.71 | 320.89 | 287.49 | 293.42 |
Operating Income | -554.48 | -454.45 | -190.36 | -320.89 | -287.49 | -293.42 |
Interest Expense | - | -0.06 | -0.01 | -0 | -0.01 | -0.01 |
Interest & Investment Income | 64.25 | 23.89 | 21.08 | 10.54 | 0.91 | 0.65 |
Currency Exchange Gain (Loss) | -46.86 | -46.86 | 0.4 | -0.62 | -1.75 | -1.83 |
EBT Excluding Unusual Items | -524.23 | -477.47 | -168.89 | -310.97 | -288.34 | -294.61 |
Gain (Loss) on Sale of Investments | - | - | - | -0.36 | -0.47 | -2.12 |
Pretax Income | -524.23 | -477.47 | -168.89 | -311.33 | -288.81 | -296.74 |
Income Tax Expense | 0.26 | - | -0.26 | -0.38 | -0.38 | -0.25 |
Net Income | -524.49 | -477.47 | -168.63 | -310.94 | -288.42 | -296.48 |
Net Income to Common | -524.49 | -477.47 | -168.63 | -310.94 | -288.42 | -296.48 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 274 | 240 | 137 | 97 | 72 | 70 |
Shares Outstanding (Diluted) | 274 | 240 | 137 | 97 | 72 | 70 |
Shares Change | 19.76% | 75.30% | 41.72% | 33.71% | 3.64% | 28.44% |
EPS (Basic) | -1.91 | -1.99 | -1.23 | -3.22 | -3.99 | -4.25 |
EPS (Diluted) | -1.91 | -1.99 | -1.23 | -3.22 | -3.99 | -4.25 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -490.37 | -375.74 | -164.95 | -249.58 | -299.92 | -265.17 |
Free Cash Flow Per Share | -1.79 | -1.57 | -1.21 | -2.58 | -4.15 | -3.81 |
Gross Margin | 100.00% | 100.00% | 100.00% | - | - | - |
Operating Margin | -14484.80% | -11905.82% | -174.09% | - | - | - |
Profit Margin | -13701.31% | -12509.14% | -154.22% | - | - | - |
Free Cash Flow Margin | -12810.14% | -9843.78% | -150.85% | - | - | - |
EBITDA | - | -452.2 | -188.12 | -317.47 | -283.88 | -290.06 |
EBITDA Margin | - | - | -172.04% | - | - | - |
D&A For EBITDA | - | 2.24 | 2.24 | 3.42 | 3.61 | 3.36 |
EBIT | -554.48 | -454.45 | -190.36 | -320.89 | -287.49 | -293.42 |
EBIT Margin | - | - | -174.09% | - | - | - |